Navigation Links
Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interaction with paliperidone ER

SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically significant increase in paliperidone exposure when paroxetine was administered with paliperidone ER.(1)

Many medications prescribed for psychiatric illnesses are metabolized in the liver by a specific enzyme called CYP2D6. Administering more than one drug metabolized by CYP2D6 may cause drug-drug interactions. Paroxetine is a potent inhibitor of the CYP2D6 enzyme, and can inhibit the metabolism of some atypical antipsychotic drugs. Approximately 50 percent of patients with schizophrenia have at least one other psychiatric or medical condition requiring medication, most commonly depression.(2)

"Drug interactions frequently occur in patients with schizophrenia because this population is often treated for multiple medical and psychiatric conditions," said Dr. Joseph Palumbo, Franchise Medical Leader for Psychiatry, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "Drug interactions are an under appreciated factor that can reduce optimal treatment outcomes in our patients. This study shows that paliperidone ER can be an important new option for patients with schizophrenia who also require treatment with an antidepressant metabolized through the CYP2D6 system."

    In this study 60 healthy male patients were randomized to receive either:

    -- Treatment A: 1 tablet of paliperidone ER 3mg (Day 1)

    -- or tr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
5. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
8. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
Post Your Comments:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...tudy shows the Prox1 gene is a two-way switch that...s to be reprogrammed so that they lose their ident..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNew...rch Hospital have discovered that a certain differ...ity that it requires the constant expression of a ...
(Date:12/1/2008)...ec. 1 GeoVax Labs, Inc.,...echnology company developing,human vaccines for d...rus) and,other infectious agents, announced today...ials will take place in twelve sites across North ...collaboration with The National Institutes of,Hea...
(Date:11/28/2008)...IS, Nov. 28 Eli Lilly an...mental New Drug Application (sNDA) from,the U.S. ... (duloxetine HCl),for the management of chronic p...he first half of 2009, adding data from a recently...is pain of the knee. , The decision does no...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Chocolate Milk 3A The Official Drink of Halloween 2863 1Chocolate Milk 3A The Official Drink of Halloween 2863 2Chocolate Milk 3A The Official Drink of Halloween 2863 3Chocolate Milk 3A The Official Drink of Halloween 2863 4Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 1Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 2Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 1Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 2Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 4Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 5Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 6Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 1Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 6
...duces TNF-alpha Production Through Inhibition,of P...ewswire/ -- Anacor,Pharmaceuticals, a privately he...ults from its placebo-controlled Phase 1 trial of,...estigation for,the treatment of psoriasis. The tri...ty comparable to existing topical,treatments for p...
... York, June 06, 2007 /PRNewswire-FirstCall/,-- XTL...as,completed the analysis of results from a Phase ...ronic Hepatitis C. This Phase I,trial was a placeb...hich evaluated the safety, tolerability and antivi...125. The study enrolled 56,patients into seven coh...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: